Immunovia AB (publ) (IMMVF) Stock Price, News & Analysis

Company Overview

Immunovia AB (publ), a diagnostic company, engages in developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on its proprietary test platform IMMray in Sweden and internationally. Its pipeline comprises early-phase research projects in collaboration with academic centers; and diagnostic tests in pancreatic cancer and rheumatoid arthritis diagnostics. Immunovia AB (publ) was founded in 2007 and is headquartered in Lund, Sweden.

Key Stats

• Today's Range: $0.05 to $0.05
• 50-Day Range: N/A
• 52-Week Range: $0.84 to $2.00
• Volume: N/A
• Average Volume: 12,942 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMMVF Stock Analysis - Frequently Asked Questions

How were Immunovia AB (publ)'s earnings last quarter?

Immunovia AB (publ) (OTCMKTS:IMMVF) released its quarterly earnings results on Friday, November, 29th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01.

Company Calendar

• Last Earnings: 11/29/2013
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:IMMVF
• CIK: N/A
• Web: www.imvaccine.com
• Phone: (902) 492-1819
• Fax: N/A
• Employees: 69
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A